Acellbia Indications/Uses

Non-Hodgkin's Lymphoma: Rituximab is indicated for the treatment of: patients with relapsed or chemoresistant low-grade of follicular, CD20-positive, B-cell non-Hodgkin's lymphoma; previously untreated patients with stage III-IV follicular lymphoma in combination with chemotherapy; patients with follicular lymphoma a maintenance treatment, after response to induction therapy; patients with CD20-positive diffuse large B-cell non-Hodgkin's lymphoma in combination with CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) chemotherapy.
Chronic Lymphocytic Leukemia: Rituximab in combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory chronic lymphocytic leukemia (CLL).
Rheumatoid Arthritis: Rituximab in combination with Methotrexate is indicated in adult patients for: the treatment of moderate to severe, active rheumatoid arthritis when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate; treatment of moderate to severe, active rheumatoid arthritis in patients with an inadequate response or intolerance to one or more tumor necrosis factor (TNF) inhibitor therapies.
Granulomatosis with Polyangiitis (Wegener's) (GPA) and Microscopic Polyangiitis (MPA): Rituximab in combination with glucocorticoids is indicated for the treatment of patients with severe active granulomatosis with polyangiitis (GPA, also known as Wegener's granulomatosis) and microscopic polyangiitis (MPA).